- Conditions
- Hematological Malignancies
- Interventions
- Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Fludarabine, Busulfan, Hematopoietic stem cell transplantation
- Radiation · Drug · Genetic
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 212
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Scleroderma, Systemic
- Interventions
- Peripheral Blood Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, Filgrastim, Fludarabine
- Biological · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 17 Years to 60 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
- Interventions
- data collection
- Drug
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 2 Months to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, methylprednisolone, total-body irradiation
- Biological · Drug · Radiation
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 4
- States / cities
- Nashville, Tennessee
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders
- Interventions
- Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, fludarabine phosphate, Melphalan, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Systemic Sclerosis
- Interventions
- RIC alloBMT w PTCy in refractory SSc
- Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders, Immune System Diseases, Common Variable Immunodeficiency
- Interventions
- e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning, GVHD Prophylaxis, Allogeneic HSC, Bisulfan, Prednisone, Cyclophosphamide, MMF, Mesna, Tacrolimus, Pentostatin, PFTs, DEXA, Bone Marrow Aspirate & Biopsy, EKG, 2D ECHO
- Drug · Procedure · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2030
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Minneapolis, Minnesota
- Conditions
- Sickle Cell Disease
- Interventions
- Hematopoietic Stem Cell Transplantation, CliniMACS, See intervention description
- Procedure · Device · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
- Interventions
- Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- nonmyeloablative allogeneic hematopoietic stem cell transplantation, donor lymphocytes, cyclosporine, total-body irradiation, fludarabine phosphate, mycophenolate mofetil, laboratory biomarker analysis, peripheral blood stem cell transplantation
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
- Interventions
- Cladribine, Cyclophosphamide, Cyclosporine, Cytarabine, Filgrastim, Hematopoietic Cell Transplantation, Mitoxantrone, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Idarubicin, Fludarabine, Multigated Acquisition Scan, Echocardiography Test, X-Ray Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Leukemia, Not Otherwise Specified, Leukemia, Other
- Interventions
- Cyclophosphamide, Specimen collection
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2035
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Hematopoietic Stem Cell Transplantation
- Interventions
- Melphalan
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, CNS Tumors
- Interventions
- Allogeneic HCT, Donor NK Cell Infusion
- Procedure · Drug
- Lead sponsor
- Monica Thakar
- Other
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 2
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
- Interventions
- Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
- Drug
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 2 Months to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Sickling Disorder Due to Hemoglobin S
- Interventions
- 131I-apamistmab, Sirolimus, Campath, Total Body Irradiation, Exchange Transfusion, Planar gamma imaging
- Drug · Radiation · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- Sirolimus, Methotrexate, Tacrolimus, Cyclosporine, MMF
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 24
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- alemtuzumab, total-body irradiation, fludarabine phosphate, cyclosporine, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, graft versus host disease prophylaxis/therapy, laboratory biomarker analysis
- Biological · Radiation · Drug + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Secondary AML, Myelodysplastic Syndrome (MDS), Secondary MDS, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia (JMML), Paroxysmal Nocturnal Hemoglobinuria (PNH), Lymphoma, Non-Hodgkin, Hodgkin Disease
- Interventions
- Stem Cell Transplantation, Miltenyi Biotec CliniMACS, Systemic chemotherapy and antibodies
- Procedure · Device · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Leukemia, Solid Tumors
- Interventions
- Clinimacs Cell Separation System, conditioning chemotherapy, DLI
- Device · Drug · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 6 Months to 74 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
- Interventions
- Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide, Mesna, Cord Blood Infusion, Busulfan, Fludarabine, Melphalan
- Radiation · Drug · Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 2 Months to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York